Autocatalytic strategy for tuning drug release from peptide-drug supramolecular hydrogel

被引:0
|
作者
Yuqin Wu [1 ]
Tian Xia [1 ]
Xiaohui Ma [1 ]
Lei Lei [1 ]
Lulu Du [1 ]
Xiaoning Xu [1 ]
Xiangyi Liu [1 ]
Yueting Shi [1 ]
Xingyi Li [1 ]
Deqing Lin [1 ]
机构
[1] Institute of Biomedical Engineering, School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical University
关键词
D O I
暂无
中图分类号
TQ460.1 [基础理论]; TQ427.26 [];
学科分类号
摘要
Peptide-drug conjugates(PDCs) composed of peptide, spacer and drug have gained extensive attention in the field of drug delivery owing to its precise control over the drug payload and architecture. However,the achievement of controllable and rapid drug release at targeted site by PDCs is still a great challenge for pharmaceutist. Herein, we introduced the histidine residue into PDCs to generate a supramolecular hydrogel via a p H-trigger strategy, which exhibited an autocatalytic effect to precisely tune drug release from PDCs hydrogel. Using indomethacin(Idm) as model drug, various PDCs(Y(Idm)EEH, Y(Idm)EEK and Y(Idm)EER) were synthesized and their self-assembling properties were investigated in terms of critical aggregation concentration(CAC), transmission electron microscopy(TEM) and rheometer. Introduction of histidine residue into PDCs presented a robust catalytic activity on the ester hydrolysis of p-nitrophenyl acetate in aqueous solution, as well conferred the autocatalytic capacity to hydrolyze the PDCs into active parent drug(Idm). Overall, we reported an autocatalytic activity of histidine residue to precisely tune drug release from PDCs hydrogels.
引用
收藏
页码:220 / 224
页数:5
相关论文
共 50 条
  • [31] Tuning drug release from polyoxazoline-drug conjugates
    Harris, J. Milton
    Bentley, Michael D.
    Moreadith, Randall W.
    Viegas, Tacey X.
    Fang, Zhihao
    Yoon, Kunsang
    Weimer, Rebecca
    Dizman, Bekir
    Nordstierna, Lars
    EUROPEAN POLYMER JOURNAL, 2019, 120
  • [32] Drug release from new bioartificial hydrogel
    Artif Cells Blood Substitutes Immobilization Biotechnol, 5 (605):
  • [33] Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
    Mo Wu
    Wei Huang
    Nan Yang
    Yanyong Liu
    Experimental Hematology & Oncology, 11
  • [34] Drug release behaviour from drug loaded LBL multilayer on hydrogel
    Chen, P.
    Wang, X.
    Pang, J.
    Dong, Y.
    Ma, X.
    Hu, X.
    MATERIALS TECHNOLOGY, 2015, 30 (03) : 159 - 161
  • [35] Peptide-Drug Conjugates with Different Linkers for Cancer Therapy
    Alas, Mona
    Saghaeidehkordi, Azam
    Kaur, Kamaljit
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (01) : 216 - 232
  • [36] Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies
    Hoppenz, Paul
    Els-Heindl, Sylvia
    Beck-Sickinger, Annette G.
    FRONTIERS IN CHEMISTRY, 2020, 8
  • [37] Novel Peptide-Drug Conjugates with Dual Anticancer Activity
    O'Flaherty, Siobhan
    Luzina, Olga A.
    Dyrkheeva, Nadezhda S.
    Krier, Ysaline
    Leprince, Jerome
    Zakharenko, Alexandra L.
    Pokrovsky, Mikhail A.
    Pokrovsky, Andrey G.
    Lavrik, Olga I.
    Salakhutdinov, Nariman F.
    Varbanov, Mihayl
    Devocelle, Marc
    Volcho, Konstantin P.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (22)
  • [38] Bridging the synthetic and biopolymer worlds with peptide-drug conjugates
    Weiss, GA
    Chamberlin, R
    CHEMISTRY & BIOLOGY, 2003, 10 (03): : 201 - 202
  • [39] Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma
    Mateos, Maria-Victoria
    Blade, Joan
    Bringhen, Sara
    Ocio, Enrique M.
    Efebera, Yvonne
    Pour, Ludek
    Gay, Francesca
    Sonneveld, Pieter
    Gullbo, Joachim
    Richardson, Paul G.
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (10) : 1 - 16
  • [40] Peptide-Drug Conjugates: A New Hope for Cancer Management
    Chavda, Vivek P.
    Solanki, Hetvi K.
    Davidson, Majid
    Apostolopoulos, Vasso
    Bojarska, Joanna
    MOLECULES, 2022, 27 (21):